Polycystic Ovary Syndrome (PCOS): Symptoms, Hormone Imbalances, and Management
Polycystic Ovary Syndrome (PCOS) is the most prevalent endocrine and metabolic disorder in reproductive-aged women, affecting 8–13% globally. Explore the standardized Rotterdam diagnostic criteria, the pathophysiology of hyperandrogenism and hyperinsulinemia, evidence-based nutritional protocols (Myo-Inositol, low-glycemic diets), and ovulation induction.
Hands-free audio narration
This educational guide is researched in accordance with our Editorial Policy and public health guidelines. It is not personal medical advice. For clinical questions, read our Medical Disclaimer or consult a qualified healthcare provider.
Quick Summary & Key Findings
PCOS is diagnosed using the Rotterdam criteria (requiring at least 2 of 3: ovulatory dysfunction, clinical/biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound). First-line management targets metabolic insulin resistance with Myo-Inositol/Metformin, combined oral contraceptives for cycle regularity, and Spironolactone for androgenic symptoms.
In women's health and reproductive endocrinology, Polycystic Ovary Syndrome (PCOS) is frequently misunderstood as strictly an ovarian disorder. In clinical reality, PCOS is a systemic neuro-endocrine and metabolic condition characterized by vicious hormonal feedback loops between the ovaries, adrenal glands, pituitary gland, and metabolic tissues.
Elevated basal Luteinizing Hormone (LH) pulses stimulate ovarian theca cells to overproduce androgens (testosterone and androstenedione). Concurrently, systemic insulin resistance drives compensatory hyperinsulinemia, which directly suppresses hepatic synthesis of Sex Hormone-Binding Globulin (SHBG)—dramatically increasing free circulating bioactive testosterone.
Navigating PCOS requires moving beyond generic advice to 'just lose weight' and implementing targeted interventions that address the underlying drivers of insulin resistance, chronic inflammation, and ovulatory dysfunction.
Pathophysiology & The Rotterdam Diagnostic Criteria
Clinical Management Strategies for PCOS Phenotypes
| Therapeutic Goal | First-Line Medical Therapies | Evidence-Based Supplements | Dietary & Lifestyle Interventions |
|---|---|---|---|
| Cycle Regularity & Endometrial Protection | Combined Oral Contraceptives (COCs), Cyclic Progestins (Provera), Levonorgestrel IUD | Myo-Inositol & D-Chiro-Inositol (40:1 physiological ratio) | Low-Glycemic Load Mediterranean diet; regular strength training to enhance insulin sensitivity. |
| Hyperandrogenism (Hirsutism & Acne) | Spironolactone (50–200 mg/day), Cyproterone acetate, Topical Eflornithine | Spearmint tea (anti-androgenic polyphenols), Zinc picolinate (30 mg/day) | Electrolysis or laser hair removal for existing terminal hair follicles. |
| Metabolic & Insulin Resistance | Metformin (1,500–2,000 mg/day extended-release), GLP-1 Receptor Agonists | Berberine (500 mg 2–3x/day with meals), Alpha-Lipoic Acid (600 mg/day) | 150 min/wk moderate aerobic exercise + 2–3 days/wk resistance exercise. |
| Ovulation Induction & Fertility | Letrozole (Femara - first-line aromatase inhibitor), Clomiphene Citrate | CoQ10 (ubiquinol 200–600 mg/day for oocyte quality), Folate (L-methylfolate) | Optimize BMI (5–10% weight loss restores spontaneous ovulation in ~50% of anovulatory women). |
Clinical Signs and Hormonal Biomarkers of PCOS
When to Consult a Reproductive Endocrinologist or Gynecologist
- Absence of menstrual periods for >3 consecutive months (amenorrhea) carrying risks of endometrial hyperplasia
- Rapid, sudden onset of severe hirsutism or voice deepening (requires immediate CT/MRI to rule out androgen-secreting tumors)
- Inability to conceive after 6 to 12 months of timed intercourse with irregular cycles
- Severe cyclic pelvic pain, which may indicate co-existing Endometriosis
Frequently Asked Questions
Dr. Anuradha Kapur, MBBS, MD, FICOG
Senior Director & Head, Obstetrics & Gynecology, Max Hospital Saket • MBBS, MD (Obstetrics & Gynecology), FICOGDr. Anuradha Kapur is the Senior Director and Head of the Department of Obstetrics & Gynecology at Max Super Speciality Hospital, Saket, New Delhi. With over 30 years of clinical experience, she specializes in high-risk pregnancies, adolescent gynecology, minimally invasive laparoscopic surgery, and menopausal health.
References & Clinical Resources
- Teede HJ, Tay CT, Laven JSE, et al.. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (2023). [Access Resource Link] — Fertility and Sterility. 120(4):767-793
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group) (2004). [Access Resource Link] — Human Reproduction. 19(1):41-47
- Legro RS, Brzyski RG, Diamond MP, et al.. Letrozole versus Clomiphene for Infertility in the Polycystic Ovary Syndrome (2014). [Access Resource Link] — New England Journal of Medicine. 371(2):119-129
Related Healthcare Guides
Reader Reviews & Clinical Q&A
Real experiences, reader questions, and verified physician guidance.
Finally a medical article that validates symptoms without dismissing them. The diagnostic checklist and hormone test breakdown gave me the confidence to request a full panel from my OB/GYN.
Patient self-advocacy backed by objective medical data is essential in women's healthcare, Claire. We hope your follow-up appointment provides clear clinical answers.
The distinction between muscular hypertonicity and weakness in this guide is spot on. Too many online articles just prescribe generic exercises without explaining individual pelvic mechanics.
Accurate anatomical nuance prevents patients from inadvertently worsening their symptoms, Hannah. Thank you for your specialized insight!